Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Maeve A. Lowery et al.|The Lancet Oncology|2023Cited by 614
Salvianolic acid B, a novel autophagy inducer, exerts antitumor activity as a single agent in colorectal cancer cellsJing Zhao, Hongming Pan|Oncotarget|2016Cited by 73
Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanibHongming Pan, Weidong Han|Scientific Reports|2014Cited by 68
1280P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)Qing Zhou, Yi‐Long Wu, Xianjun Yu et al.|Annals of Oncology|2021Cited by 2
156P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase Ib studyC. Cui, Jun Guo, Hongming Pan et al.|Annals of Oncology|2021Cited by 1